[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 28.0, "open": 28.27, "dayLow": 28.01, "dayHigh": 29.28, "regularMarketPreviousClose": 28.0, "regularMarketOpen": 28.27, "regularMarketDayLow": 28.01, "regularMarketDayHigh": 29.28, "payoutRatio": 0.0, "beta": 1.01, "forwardPE": -6.889811, "volume": 2508676, "regularMarketVolume": 2508676, "averageVolume": 2203132, "averageVolume10days": 3125390, "averageDailyVolume10Day": 3125390, "bid": 28.95, "ask": 29.18, "bidSize": 24, "askSize": 24, "marketCap": 4019851520, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 29.34, "priceToSalesTrailing12Months": 7.0157413, "fiftyDayAverage": 18.6425, "twoHundredDayAverage": 17.615025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3832445184, "profitMargins": -0.25902998, "floatShares": 118912554, "sharesOutstanding": 138258000, "sharesShort": 12984322, "sharesShortPriorMonth": 12418563, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0939, "heldPercentInsiders": 0.044320002, "heldPercentInstitutions": 0.77509004, "shortRatio": 5.35, "shortPercentOfFloat": 0.121199995, "impliedSharesOutstanding": 138258000, "bookValue": 3.781, "priceToBook": 7.689765, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -148416992, "trailingEps": -1.2, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 6.689, "enterpriseToEbitda": -44.879, "52WeekChange": 0.33616734, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 29.075, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 46.15385, "targetMedianPrice": 39.0, "recommendationMean": 1.78571, "recommendationKey": "buy", "numberOfAnalystOpinions": 13, "totalCash": 898172032, "totalCashPerShare": 6.496, "ebitda": -85396000, "totalDebt": 713286016, "quickRatio": 4.667, "currentRatio": 4.868, "totalRevenue": 572976000, "debtToEquity": 137.222, "revenuePerShare": 4.395, "returnOnAssets": -0.0596, "returnOnEquity": -0.37111, "grossProfits": 572976000, "freeCashflow": -48370124, "operatingCashflow": 21845000, "grossMargins": 1.0, "ebitdaMargins": -0.14904, "operatingMargins": -5.96211, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketPrice": 28.81, "postMarketChange": -0.2650013, "regularMarketChange": 1.075, "regularMarketDayRange": "28.01 - 29.28", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2203132, "fiftyTwoWeekLowChange": 19.505001, "fiftyTwoWeekLowChangePercent": 2.0381403, "fiftyTwoWeekRange": "9.57 - 29.34", "fiftyTwoWeekHighChange": -0.2649994, "fiftyTwoWeekHighChangePercent": -0.009032018, "fiftyTwoWeekChangePercent": 33.616734, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1754596800, "earningsTimestampEnd": 1754596800, "earningsCallTimestampStart": 1754884800, "earningsCallTimestampEnd": 1754884800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.2, "epsForward": -4.22, "epsCurrentYear": -0.18247, "priceEpsCurrentYear": -159.34128, "fiftyDayAverageChange": 10.432501, "fiftyDayAverageChangePercent": 0.55960846, "twoHundredDayAverageChange": 11.459976, "twoHundredDayAverageChangePercent": 0.65057963, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "postMarketTime": 1757115584, "regularMarketTime": 1757102401, "longName": "Arrowhead Pharmaceuticals, Inc.", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Arrowhead Pharmaceuticals, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": -0.9114404, "regularMarketChangePercent": 3.83929, "regularMarketPrice": 29.075, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]